CA1
Carbonic anhydrase 1
As of the edition of 20 October 2026, CA1 (carbonic anhydrase 1, UniProt P00915) has 5 drugs tested at it and 9 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00915
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 57
- Disease areas
- Lungs and airways; Nervous system; Heart and blood vessels; Nutrition and metabolism; Eye; Inherited and neonatal; Mental health; Hormones
- Registered trials of its drugs
- 107
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Acetazolamide | Marketed | Phase 4 | none listed |
| Methazolamide | Marketed | Phase 4 | none listed |
| Methocarbamol | Marketed | Phase 4 | none listed |
| Polmacoxib | Marketed | Phase 3 | none listed |
| Dichlorphenamide | Marketed | Phase 3 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Undetermined | 6 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| União Química Farmacêutica Nacional S/A | Route B |
| CrystalGenomics | Route B |
| Pfizer | Route B |
The other 6 companies at CA1
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at CA1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.